Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

DFMO treatment improves hair growth, muscle tone, and development in Bachmann-Bupp syndrome patients.

Stopping mitochondrial respiration can prevent brain cancer spread in skin cancer patients, and plant compound β-sitosterol could help achieve this.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

The framework helps predict adverse effects of blood thinners, improving drug selection for atrial fibrillation.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Finasteride use may increase the risk of male breast cancer.

Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Trastuzumab deruxtecan is effective for advanced breast cancer but has side effects like nausea and fatigue.

Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.

The folate-cyclodextrin conjugate targets cancer cells more precisely, potentially reducing chemotherapy side effects.

Targeted cancer therapies can cause skin side effects, but activating SOS in the skin may help reduce them.

HSA nanoparticles can improve tamoxifen delivery for breast cancer treatment, reducing side effects.

In 2024, the FDA approved 50 new drugs, including treatments for hair loss, anemia, high blood pressure, and Alzheimer's.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.

Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.

Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.

Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.

The new Brigatinib nanocarrier is more effective against lung cancer cells than the free drug.

Ritlecitinib effectively improves hair regrowth and physician satisfaction in severe alopecia areata over time.